News
JNJ offers resilience and income, while Apple fuels long-term growth???ideal picks for a stress-free retirement portfolio.
3d
Zacks Investment Research on MSNHere is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending StockJohnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Johnson & Johnson (NYSE:JNJ) is one of the top cheap pharmaceutical stocks to buy now. On July 29, Johnson & Johnson ...
STAAR Surgical's ( NASDAQ: STAA) largest holder is making a demand for books and records on the process that led to its ...
7d
Zacks.com on MSNJNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
23d
MarketBeat on MSNJNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is NowDetailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
JNJ offers a dividend yield of 3.1%.ConclusionWall Street analysts are very bullish about Intuitive Surgical and are cautiously optimistic about Eli Lilly and Johnson & Johnson.
However, the increase in PG and JNJ stocks has been far from consistent. Returns for PG stock were 21% in 2021, -5% in 2022, and -1% in 2023, while for JNJ stock were 11%, 6%, and -9% ...
Johnson & Johnson JNJ will report fourth-quarter and full-year 2022 results on Jan 24, before market open. In the last reported quarter, the company delivered an earnings surprise of 2.41%.
Johnson & Johnson (NYSE: JNJ) revenue grew at a CAGR of 4.1% from $70.0 billion in 2015 to $82.0 billion in 2019, and it is estimated to top $85 billion in 2020, led by its pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results